Wellbutrin SR

Major Depressive Disorder

Wellbutrin SR is primarily indicated for the treatment of major depressive disorder (MDD). It is a sustained-release formulation of bupropion, which means the medication is released into the bloodstream slowly over several hours. It is used to help manage symptoms of clinical depression, such as:

• Persistent feelings of sadness, hopelessness, or worthlessness.
• Loss of interest or pleasure in usual activities.
• Significant changes in appetite or weight.
• Sleep disturbances, including insomnia or oversleeping.
• Fatigue or loss of energy.
• Difficulty thinking, concentrating, or making decisions.

Other Uses of Bupropion

While Wellbutrin SR is specifically approved for major depressive disorder, its active ingredient, bupropion, is used in other formulations for different conditions. These include:

• Seasonal Affective Disorder (SAD): Preventing depressive episodes that occur at the same time each year, typically during the fall and winter months.
• Smoking Cessation: Helping people quit smoking by reducing nicotine cravings and withdrawal symptoms.

Healthcare providers determine the specific formulation and dosage based on the condition being treated and the patient's individual needs.

Wellbutrin SR belongs to a class of medications known as aminoketones. It works differently than many other common antidepressants because it does not primarily affect serotonin. Instead, it is believed to influence two other neurotransmitters: norepinephrine and dopamine.

Neurotransmitters are chemical messengers that brain cells use to communicate. In people with depression, these chemicals may be out of balance. Wellbutrin SR is thought to work by:

• Increasing the amount of active dopamine and norepinephrine available to the brain.
• Blocking the reabsorption of these chemicals, allowing them to stay active for longer periods.

Although the exact mechanism is not fully understood, this process is believed to help restore chemical balance and improve mood and feelings of well-being. The sustained-release (SR) formulation is designed to release the medication slowly into the bloodstream over several hours.

Common Side Effects

Many people taking Wellbutrin SR experience mild side effects. These may include:

• Dry mouth and changes in taste
• Headache
• Nausea, vomiting, or stomach pain
• Constipation
• Loss of appetite and weight loss
• Dizziness or tremors
• Excessive sweating
• Ringing in the ears
• Difficulty falling asleep or staying asleep
• Anxiety or nervousness

Serious Side Effects

Contact a healthcare provider immediately if you experience any of the following serious symptoms:

• Seizures
• Confusion, hallucinations, or irrational fears
• Rapid, pounding, or irregular heartbeat
• Severe muscle or joint pain
• Chest pain

Seek emergency medical help if you have signs of an allergic reaction, such as a skin rash, hives, itching, or swelling of the face, lips, tongue, or throat. Difficulty breathing or swallowing also requires immediate attention.

Wellbutrin SR may cause changes in mental health or behavior. This can include new or worsening depression, suicidal thoughts, panic attacks, agitation, or aggression.

Suicidal Thoughts and Behaviors

Wellbutrin SR and other antidepressant medications may increase the risk of suicidal thoughts and actions in children, adolescents, and young adults. This risk is highest during the first few months of treatment or when the dose is adjusted. Families and caregivers are advised to monitor for worsening depression, sudden changes in behavior, or suicidal ideation.

Seizure Risk

This medication is associated with a dose-related risk of seizures. The risk increases with higher doses or in the presence of certain medical conditions. Wellbutrin SR is contraindicated in individuals with a history of seizure disorders or those with a current or prior diagnosis of bulimia or anorexia nervosa, as these conditions significantly increase the likelihood of seizures.

Contraindications

• Seizure Disorders: Not for use in patients with a history of seizures.
• Eating Disorders: Not for use in patients with a current or prior diagnosis of anorexia nervosa or bulimia.
• Abrupt Withdrawal: Use is contraindicated in patients undergoing abrupt discontinuation of alcohol, benzodiazepines, barbiturates, or antiepileptic drugs.
• MAO Inhibitors: Use with Monoamine Oxidase Inhibitors (MAOIs) is prohibited. At least 14 days should pass between stopping an MAOI and starting Wellbutrin SR.

Neuropsychiatric Symptoms

Some patients may experience serious neuropsychiatric symptoms, including agitation, anxiety, panic attacks, insomnia, irritability, hostility, aggressiveness, impulsivity, or mania. Patients with bipolar disorder may be at higher risk for switching into a manic or mixed episode when taking antidepressants.

Blood Pressure and Eye Health

Wellbutrin SR can cause elevations in blood pressure. Regular blood pressure monitoring is recommended during treatment. Additionally, this medication can cause pupillary dilation, which may trigger an angle-closure glaucoma attack in patients with anatomically narrow angles who have not had a preventive procedure.

Severe Allergic Reactions

Anaphylactic reactions and severe skin reactions, such as Stevens-Johnson syndrome, have been reported. Treatment should be discontinued immediately if a skin rash, hives, or other signs of a hypersensitivity reaction occur.

Pregnancy

The safety of Wellbutrin SR during pregnancy is not fully established. Clinical data regarding the risk of congenital malformations are inconsistent. Some studies have suggested a potential increase in the risk of heart defects when taken during the first trimester, while other research has not found a significant association.

Decisions regarding the use of Wellbutrin SR during pregnancy involve weighing the risks of the medication against the risks of untreated depression or other conditions. Patients are encouraged to discuss their specific situation with a healthcare professional before making changes to their treatment.

Breastfeeding

Bupropion and its metabolites are excreted in human milk. There have been rare reports of seizures in nursing infants exposed to the drug. Because of the potential for serious adverse reactions, a healthcare provider should help determine whether to continue breastfeeding or discontinue the medication, based on the clinical necessity for the mother.

Dosage Forms

Wellbutrin SR is supplied as a film-coated, sustained-release tablet for oral administration. This formulation is specifically engineered to release the active ingredient at a controlled rate over an extended period.

Formulation Characteristics

• The tablets are film-coated to assist with swallowing.
• The sustained-release mechanism requires the tablet to remain intact to function correctly.
• Patients are advised to swallow the tablets whole and avoid crushing, chewing, or breaking them, as doing so can cause the medication to be released too rapidly.

FDA Approval and Indications

Wellbutrin SR is approved by the U.S. Food and Drug Administration (FDA) for the treatment of major depressive disorder. It is a sustained-release tablet, which means the active ingredient, bupropion hydrochloride, is released into the body over a period of several hours.

Boxed Warning

The FDA has issued a boxed warning for Wellbutrin SR, the most serious type of warning required for prescription drugs. This warning states that antidepressants may increase the risk of suicidal thoughts and behaviors in children, adolescents, and young adults. It is not approved for use in pediatric patients, and healthcare providers must monitor all patients closely for clinical worsening or suicidal tendencies.

Safety and Regulatory History

The FDA has monitored and updated safety labeling for bupropion products over time, focusing on several key areas:

• Seizure Risk: Regulatory labeling emphasizes that the risk of seizures is dose-related. The FDA has established specific dosing limits to minimize this risk.
• Neuropsychiatric Symptoms: The FDA previously required warnings regarding serious neuropsychiatric events. While some requirements were modified following large-scale safety trials, the agency continues to advise monitoring for agitation, hostility, and depression.
• Generic Availability: The FDA has approved multiple generic versions of bupropion SR, determining them to be therapeutically equivalent to the brand-name drug.

Managing Discontinuation

It is important not to stop taking Wellbutrin SR without first consulting your doctor. Stopping the medication suddenly may lead to withdrawal symptoms or a return of the condition being treated.

Potential Withdrawal Symptoms

While not everyone experiences withdrawal, some individuals may report symptoms when the medication is stopped too quickly. These can include:

• Irritability or agitation
• Anxiety
• Insomnia or other sleep disturbances
• Headaches
• Dizziness
• Sensory disturbances

Tapering the Dose

To minimize the risk of withdrawal, healthcare providers typically recommend a gradual reduction in dosage. This process, known as tapering, allows the body to adjust slowly to the decreasing levels of the medication. Your doctor will determine the best schedule for reducing your dose based on your specific needs and how long you have been taking the drug.